Emerging research suggest this peptide, a dual agonist targeting both GLP-1 and GIP , may provide a significant advancement for obesity management . Preliminary patient investigations have shown considerable decreases in abdominal mass , potentially surpassing existing weight-loss medications . Nevertheless , additional study is required to complet